About: Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $324.55 (+0.97%)
KRYS NASDAQ Krystal Biotech Inc
Krystal Biotech Inc share price
Atividade de preço de KRYS
Último preço
$ 324,550
Variação (24h)
3,13 USD (0,97%)
Volume
190.67K
Volume (média 4 sem.)
-
Abertura
$ 323,77
Variação do dia
$ 319,43 - $ 326,98
Fechamento anterior
$ 321,42
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
KRYS price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals